Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, IR, Iran.
Lipids Health Dis. 2020 Feb 17;19(1):25. doi: 10.1186/s12944-020-1198-x.
There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings are controversial. This systematic review and meta-analysis were aimed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders.
We performed a comprehensive search of the following online databases up to November 2018: Cochrane Library, PubMed, Embase, and Web of Science. The relevant articles were assessed for quality of studies using the Cochrane risk of bias tool.
Out of 2459 citations, 31 articles were appropriate for including to the current meta-analysis. The pooled results indicated that resveratrol use significantly decreased total cholesterol [weighted mean difference (WMD) = - 7.65 mg/dL; 95% CI, - 12.93, - 2.37; P < 0.01; I: 83.4%] and increased gamma-glutamyl transferase (GGT) concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; P < 0.01; I: 20.1%). We found no significant effect of resveratrol supplementation on triglycerides (WMD = - 5.84 mg/dL; 95% CI, - 12.68, 1.00; P = 0.09; I: 66.8%), LDL- (WMD = -2.90 mg/dL; 95% CI, - 10.88, 5.09; P = 0.47; I: 96.0%), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, - 0.80, 1.78; P = 0.45; I: 74.0%), alanine aminotransferase (ALT) (WMD = -0.14 U/l; 95% CI, - 3.69, 3.41; P = 0.93; I: 79.6%), and aspartate aminotransferase (AST) (WMD = -0.34 U/l; 95% CI, - 2.94, 2.27; P = 0.80; I: 88.0%) concentrations.
This meta-analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders.
目前有一些临床试验研究了白藜芦醇补充剂对代谢综合征（MetS）及相关疾病患者的血脂谱和肝酶的影响，但它们的结果存在争议。本系统评价和荟萃分析旨在确定白藜芦醇补充剂对 MetS 及相关疾病患者血脂谱和肝酶的影响。
我们对以下在线数据库进行了全面检索，截止到 2018 年 11 月：Cochrane 图书馆、PubMed、Embase 和 Web of Science。使用 Cochrane 偏倚风险工具评估相关文章的研究质量。
在 2459 条引文中有 31 篇文章适合纳入当前的荟萃分析。汇总结果表明，白藜芦醇的使用显著降低了总胆固醇[加权均数差（WMD）=-7.65mg/dL；95%CI，-12.93，-2.37；P<0.01；I²：83.4%]和增加了γ-谷氨酰转移酶（GGT）浓度（WMD=1.76U/L；95%CI，0.58，2.94；P<0.01；I²：20.1%）。我们发现白藜芦醇补充剂对甘油三酯（WMD=-5.84mg/dL；95%CI，-12.68，1.00；P=0.09；I²：66.8%）、低密度脂蛋白（WMD=-2.90mg/dL；95%CI，-10.88，5.09；P=0.47；I²：96.0%）、高密度脂蛋白胆固醇（WMD=0.49mg/dL；95%CI，-0.80，1.78；P=0.45；I²：74.0%）、丙氨酸氨基转移酶（ALT）（WMD=-0.14U/L；95%CI，-3.69，3.41；P=0.93；I²：79.6%）和天冬氨酸氨基转移酶（AST）（WMD=-0.34U/L；95%CI，-2.94，2.27；P=0.80；I²：88.0%）浓度没有显著影响。
本荟萃分析表明，白藜芦醇补充剂可显著降低 MetS 及相关疾病患者的总胆固醇和增加 GGT 浓度，但不影响甘油三酯、低密度脂蛋白、高密度脂蛋白胆固醇、ALT 和 AST 浓度。这表明白藜芦醇可能对 MetS 及相关疾病患者具有潜在的心脏保护作用。
